Oxalic Acid

Oxalic Acid

SCHEMBL234978

O.O.O=C([O-])C(=O)[O-].O=C([O-])C(=O)[O-].O=C([O-])C(=O)[O-].O=C([O-])C(=O)[O-].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+]

nearest known ligand 0.78

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1SLC6A4

The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
CA4 P22748 5/20 0.78
FAHD1 Q6P587 1/20 0.78
MEN1 O00255 1/20 0.46
LDHA P00338 1/20 0.46
BLM P54132 1/20 0.46
KMT2A Q03164 1/20 0.46
CA1 P00915 2/20 0.46
LMNA P02545 2/20 0.36
CASP1 P29466 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxalic Acid SCHEMBL7981840 1.00 CA4 (0.78) CA4FAHD1MEN1LDHABLM
Oxalic Acid SCHEMBL7620105 1.00 CA4 (0.78) CA4FAHD1MEN1LDHABLM
Oxalic Acid SCHEMBL28387560 1.00 CA4 (0.78) CA4FAHD1MEN1LDHABLM
Oxalic Acid SCHEMBL169342 1.00
Oxalic Acid SCHEMBL2722478 1.00 CA4 (0.78) CA4FAHD1MEN1LDHABLM
Oxalic Acid SCHEMBL23794556 0.94 CA4 (0.70) CA4FAHD1MEN1LDHABLM
Oxalic Acid SCHEMBL25340214 0.94 CA4 (0.70) CA4FAHD1MEN1LDHABLM
Oxalic Acid SCHEMBL21047559 0.94 CA4 (0.70) CA4FAHD1MEN1LDHABLM
Oxalic Acid SCHEMBL25291950 0.94 CA4 (0.70) CA4FAHD1MEN1LDHABLM
Oxalic Acid SCHEMBL20495937 0.94 CA4 (0.70) CA4FAHD1MEN1LDHABLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4507722-A1 NANOEMULSION UNIVERSAL INFLUENZA VACCINE Bluewillow Biologics, Inc. (US) 2025-02-19 EP claimed
US-20240398854-A1 OPHTHALMIC FORMULATIONS AND METHODS FOR THEIR USE Panaseea, LLC (US) 2024-12-05 US claimed
US-20240058434-A1 NANOEMULSION UNIVERSAL INFLUENZA VACCINE BLUEWILLOW BIOLOGICS, INC. (US) 2024-02-22 US claimed
WO-2023200764-A1 NANOEMULSION UNIVERSAL INFLUENZA VACCINE BLUEWILLOW BIOLOGICS, INC. (US) 2023-10-19 WO claimed
US-20190209471-A1 BUFFERED COMPOSITIONS AND METHODS FOR THEIR USE IN SURFACE TREATMENTS Panaseea, LLC (US) 2019-07-11 US claimed
CN-109930011-A A kind of vanadium aluminum separation method containing vanadium solution 武汉科技大学 2019-06-25 CN claimed
CN-109825717-A A method of recycling magnesium, iron and aluminium step by step from containing vanadium solution 武汉科技大学 2019-05-31 CN claimed
CN-105226264-B A kind of sodium-ion battery richness sodium positive electrode and preparation method thereof and sodium-ion battery 北京理工大学 2018-12-14 CN claimed
CN-106082722-B A kind of cementitious material and its application 昆明理工大学 2018-08-31 CN claimed
CN-106007430-B A kind of copper ashes base iron system oxalate chemical bonding material and application thereof 昆明理工大学 2018-06-19 CN claimed
WO-2010036938-A2 NANOEMULSION THERAPEUTIC COMPOSITIONS AND METHODS OF USING THE SAME NANOBIO CORPORATION (US) 2010-04-01 WO claimed
US-20100075914-A1 METHODS FOR TREATING HERPES VIRUS INFECTIONS NANOBIO CORPORATION 2010-03-25 US claimed
US-20090304799-A1 NANOEMULSION INFLUENZA VACCINE NANOBIO CORPORATION 2009-12-10 US claimed
US-20090269380-A1 METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS NANOBIO CORPORATION 2009-10-29 US claimed
US-20090269394-A1 METHODS AND COMPOSITIONS FOR TREATING ONCHOMYCOSIS NANOBIO CORPORATION 2009-10-29 US claimed
WO-2009132342-A1 NANOEMULSIONS FOR TREATING FUNGAL, YEAST AND MOLD INFECTIONS NANOBIO CORPORATION (US) 2009-10-29 WO claimed
WO-2009131995-A1 NANOEMULSION INFLUENZA VACCINE NANOBIO CORPORATION (US) 2009-10-29 WO claimed
WO-2009132343-A1 NANOEMULSIONS FOR TREATING ONCHOMYCOSIS NANOBIO CORPORATION (US) 2009-10-29 WO claimed
WO-2009129470-A2 METHODS FOR TREATING HERPES VIRUS INFECTIONS NANOBIO CORPORATION (US) 2009-10-22 WO claimed
CN-1064986-C Composition for cleaning and etching electronic display and substrate LEE KI WON (KR) 2001-04-25 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090269394-A1 METHODS AND COMPOSITIONS FOR TREATING ONCHOMYCOSIS DPM1, ERG28, POLR1C CA4 1545/4885FAHD1 409/4885MEN1 969/4885
US-20100075914-A1 METHODS FOR TREATING HERPES VIRUS INFECTIONS STING1, IFNG, NGF CA4 287/4885FAHD1 3104/4885MEN1 4237/4885
US-20090269380-A1 METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS DPM1, ERG28, CYP51A1 CA4 526/4885FAHD1 1134/4885MEN1 624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.